contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-the-annual-general-meeting-in-klaria-pharma-holding-ab-publ

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapy areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of the alginate-based polymer film. The film attaches to the patient's oral mucosa, which enables the distribution of pharmaceuticals in the body. The head office is located in Uppsala. 

Klaria Pharma Holding

Today, the annual general meeting of 2023 was held in Klaria Pharma Holding AB (publ). Below follows a summary of the resolutions passed at the annual general meeting (all in accordance with...

<div class="abstract"><p>Today, the annual general meeting of 2023 was held in Klaria Pharma Holding AB (publ). Below follows a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company's website www.klaria.com).</p></div><ul><li>It was resolved to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2022.</li><li>It was resolved that the company's available funds shall be carried forward in new account.</li><li>It was unanimously resolved to discharge the board of directors and the CEO from liability for their management of the company's business during the financial year 2022.</li><li>It was resolved to re-elect&nbsp;Fredrik Hübinette, Scott&nbsp;Boyer&nbsp;and Anders Jacobson as board members. Fredrik Hübinette was re-elected as chairman of the board. &nbsp;&nbsp;</li><li>It was resolved to re-elect the accounting firm BDO Mälardalen AB as auditor with authorized auditor Niclas Nordström as auditor-in-charge.</li><li>The fees payable to the members of the board of directors were determined to SEK 200,000 per board member not employed by the company. Scott Boyer and Fredrik Hübinette are employed by the company, entailing that fees will only be paid to Anders Jacobson. It was resolved that the company's auditor shall be paid in accordance with approved invoices.</li><li>It was resolved to change the limits in the articles of association with respect to share capital and number of shares, whereby the company's share capital shall be not less than SEK 1,700,000 and not more than SEK 6,800,000 and the number of shares shall be no less than 100,000,000 and no more than 400,000,000.</li><li>It was resolved to authorise the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company's share capital may be increased by an amount corresponding to 20 per cent of the share capital and number of shares in the company as of on the date the board of directors make use of the authorisation.</li></ul>

Stay up to date with our newsletter